TARGETED ACTION FOR CURING TRAUMA INDUCED COAGULOPATHY (TACTIC)

Trauma remains one of the world’s biggest contributors to the global burden of disease.

Over 161,000 deaths from injury in the 28 member countries of the EU were recorded in 2015. Nearly half of all trauma fatalities result from haemorrhage, with many patients developing a clotting disorder within minutes of injury (Trauma Induced Coagulaopthy:TIC) or during their clinical care that worsens bleeding and hampers emergency surgery.

Current treatment of bleeding and coagulopathy is based on empiric “blind” administration of blood products, with large variations in practice between trauma centres.

Targeted Action for Curing Trauma Induced Coagulopathy (TACTIC) was a five-year (2013-2018) comprehensive programme of comparative clinical research that recruited patients from a network of specialist trauma centres in Amsterdam, Cologne, Copenhagen, London, Oslo and Oxford to compare the effectiveness of different current practices across Europe by:

  • Defining the diversity and health economics (costs and health outcomes) of existing treatment strategies across Europe
  • Determining the pathophysiology of TIC by detailing the patient’s molecular and functional clotting response to injury and existing coagulation therapy
  • Enabling the diagnosis of ‘normocoagulable’ patients and different patterns of TIC
  • Delivering the evidence and tools for the accurate measurement of disease burden and efficacy of treatment, in the context of acute-phase mortality and longer-term patient outcomes (e.g. organ failure)
  • Enabling the intelligent development of an evidence-based personalised, targeted treatment algorithm to correct functional coagulation
  • Conducting a European multicentre randomised control trial that will deliver universal guidelines for the monitoring and treatment of coagulopathy

More detailed information about Work Packages and participants can be found on the TACTIC website

Contact

Principal Investigator: Professor Karim Brohi

 

Share this page